Search Result

Isoforms Recommended:	ATR

Results for "

ATR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (56) Acyltransferase (3) Adrenergic Receptor (1) AMPK (1) Amyloid-β (3) Apoptosis (15) Autophagy (1) Bacterial (4) BCL6 (1) Biochemical Assay Reagents (1) CDK (5) Checkpoint Kinase (Chk) (1) CMV (3) DNA Alkylator/Crosslinker (1) DNA-PK (1) DNA/RNA Synthesis (4) Drug Derivative (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) HBV (2) Hedgehog (2) Histone Methyltransferase (1) HSV (4) Influenza Virus (1) Interleukin Related (1) Isotope-Labeled Compounds (2) JNK (3) MDM-2/p53 (2) MEK (1) mTOR (4) Nucleoside Antimetabolite/Analog (3) Orthopoxvirus (2) p38 MAPK (3) PARP (1) PD-1/PD-L1 (2) PI3K (1) PROTAC Linkers (1) PROTACs (4) Reference Standards (5) Reverse Transcriptase (1) Small Interfering RNA (siRNA) (6) Src (1) STAT (2) STING (2)
By Research Areas:	Cancer (79) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (3) siRNAs (6)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of *ATR* (Ataxia Telangiectasia and Rad3 related) protein kinase (K_i=6 nM). ATR kinase substrate peptide inhibits *ATR* activity by competing with *ATR* kinase ATP-binding sites to block *ATR* mediated signaling. ATR kinase substrate peptide can be used to study the role of *ATR* kinase in DNA damage response .

HY-161616

ATR-IN-30	ATM/ATR	Cancer
ATR-IN-30 is a selective *ATR* ligand, and can be used for synthesis of ATR PROTACs, such as PROTAC ATR degrader-2 (HY-161615) .

HY-153462

ATR-IN-24	ATM/ATR	Cancer
ATR-IN-24 (Compound 1) is a *ATR* inhibitor. ATR-IN-24 has anticancer activity .

HY-144435

ATR-IN-11	ATM/ATR	Cancer
ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease .

HY-145450

ATR-IN-9	ATM/ATR	Cancer
ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC₅₀ of 10 nM .

HY-142924

ATR-IN-8	ATM/ATR	Cancer
ATR-IN-8 is a potent inhibitor of *ATR. ATR* is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3) .

HY-151915

ATR-IN-20	ATM/ATR mTOR	Cancer
ATR-IN-20 is a potent *ATR* (ATM/ATR) inhibitor with an IC₅₀ of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC₅₀ of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects .

HY-144436

ATR-IN-12	ATM/ATR	Cancer
ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC₅₀ value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase .

HY-147565

ATR-IN-13	ATM/ATR	Cancer
ATR-IN-13 (compound A9) is a potent *ATR* kinase inhibitor, with an IC₅₀ of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .

HY-174828

ATR/PARP1-IN-1	PARP ATM/ATR Apoptosis	Cancer
ATR/PARP1-IN-1 is a potent *ATR* and PARP1 dual inhibitor with IC₅₀s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change .

HY-149952

ATR-IN-23	ATM/ATR	Cancer
ATR-IN-23 (Compound 34) is a potent and selective *ATR* inhibitor with an IC₅₀ of 1.5 nM. ATR-IN-23 has potent antiproliferative effects on LoVo cells and synthetic lethality on HT-29 cells, and can be used in the study of DNA damage response (DDR)-deficient cancers .

HY-176742

ATR-258	Adrenergic Receptor	Metabolic Disease
ATR-258 is a GRK2-biased β₂AR partial agonist. ATR-258 is a competitive β₁AR antagonist and shows weak partial agonist activity at β₃AR at 10 μM. ATR-258 promotes glucose control and decreases lipid accumulation in obese mice with reduced side effects. ATR-258 can be used for T2DM research .

HY-P991272

ATR-107	Interleukin Related	Inflammation/Immunology
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .

HY-147566

ATR-IN-14	ATM/ATR	Cancer
ATR-IN-14 (compound 1) is a potent *ATR* kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC₅₀ of 64 nM .

HY-142671

ATR-IN-5	ATM/ATR	Cancer
ATR-IN-5 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .

HY-153729

ATR-IN-29	ATM/ATR	Cancer
ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC₅₀ value of 1 nM. ATR-IN-29 shows antiproliferative activity .

HY-153400

ATR-IN-22	ATM/ATR	Cancer
ATR-IN-22 (Compound 34) is an orally active *ATR* inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC₅₀ <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer .

HY-142672

ATR-IN-6	ATM/ATR	Cancer
ATR-IN-6 is a potent inhibitor of *ATR. ATR* is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .

HY-147569

ATR-IN-17	ATM/ATR	Cancer
ATR-IN-17 (compound 88) is a potent *ATR* kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC₅₀ of 1 nM .

HY-147568

ATR-IN-16	ATM/ATR	Cancer
ATR-IN-16 (compound 46) is a potent *ATR* kinase inhibitor. ATR-IN-16 shows good anticancer activity in LoVo cells, with an IC₅₀ of 410 nM .

HY-147570

ATR-IN-18	ATM/ATR	Cancer
ATR-IN-18 (compound 2) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 0.69 nM. ATR-IN-18 shows antiproliferative activity in LoVo cells, with an IC₅₀ of 37.34 nM. ATR-IN-18 has anti-tumor activity .

HY-147190

ATR-IN-19	ATM/ATR	Cancer
ATR-IN-19 (Compound 15 R-configure) is an *ATR* inhibitor .

HY-153393

ATR-IN-21	ATM/ATR	Cancer
ATR-IN-21 (compound 60) is a potent *ATR* inhibitor with an IC₅₀ value of <1000 nM .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent *ATR* kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC₅₀ values of 47, 663 and 5131 nM, respectively .

HY-144214

ATR-IN-10	ATM/ATR	Cancer
ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent *ATR* (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-169930

ATR kinase-IN-2	ATM/ATR	Cancer
ATR kinase-IN-2 (Compound I-G-27) is a ATR protein kinase inhibitor with the K_i of 0.01 ~ 1 μΜ and can be used for study of cancer .

HY-169931

ATR kinase-IN-3	ATM/ATR	Cancer
ATR kinase-IN-3 (Compound I-G-28) is a ATR protein kinase inhibitor with the K_i of 0.01 ~ 1 μΜ and can be used for study of cancer .

HY-RS01245

ATR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ATR Human Pre-designed siRNA Set A contains three designed siRNAs for ATR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ATR Human Pre-designed siRNA Set A ATR Human Pre-designed siRNA Set A

HY-RS01247

Atr Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Atr Rat Pre-designed siRNA Set A contains three designed siRNAs for Atr gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Atr Rat Pre-designed siRNA Set A Atr Rat Pre-designed siRNA Set A

HY-RS01246

Atr Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Atr Mouse Pre-designed siRNA Set A contains three designed siRNAs for Atr gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Atr Mouse Pre-designed siRNA Set A Atr Mouse Pre-designed siRNA Set A

HY-111451

Tuvusertib M1774; ATR inhibitor 1	ATM/ATR	Cancer
Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active *ATR* inhibitor extracted from patent WO2015187451A1, compound I-l, with a K_i value below 1 μΜ .

HY-136270

Gartisertib 2 Publications Verification VX-803; M4344; ATR inhibitor 2	ATM/ATR	Cancer
Gartisertib (VX-803) is an ATP-competitive, orally active, and selective *ATR* inhibitor, with a K_i of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC₅₀ of 8 nM. Antitumor activity .

HY-139609

Camonsertib RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective *ATR* kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-100399

Nevanimibe PD-132301; ATR-101	Acyltransferase Apoptosis	Cancer
Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC₅₀ of 9 nM. Nevanimibe inhibits ACAT2 with an EC₅₀ of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer .

HY-139558

Zapnometinib PD0184264; ATR-002	MEK Influenza Virus Bacterial	Infection Cancer
Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC₅₀ of 5.7 nM. Zapnometinib exhibits antiviral activity against influenza virus and antibacterial activities .

HY-100399A

Nevanimibe hydrochloride 3 Publications Verification PD-132301 hydrochloride; ATR101 hydrochloride	Acyltransferase Apoptosis	Cancer
Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC₅₀ of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC₅₀ of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .

HY-100399AR

Nevanimibe hydrochloride (Standard) PD-132301 hydrochloride (Standard); ATR101 hydrochloride (Standard)	Reference Standards Acyltransferase Apoptosis	Cancer
Nevanimibe hydrochloride (Standard) is the analytical standard of Nevanimibe hydrochloride. This product is intended for research and analytical applications. Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .

HY-161615

*PROTAC ATR* degrader-2**	Apoptosis PROTACs	Cancer
PROTAC ATR degrader-2 (Compound 8i) is a PROTAC degrader for *ATR, through of . PROTAC ATR* degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ of 22.9 and 34.5 nM. APROTAC ATR degrader-2 induces apoptosis, inhibits proliferations of AML cells. PROTAC ATR degrader-2 exhibits good pharmacokinetics charachers and antitumor efficacy against AML in mouse model. (Pink: ATR ligand (HY-161616); Blue:E3 ligase ligand Lenalidomide (HY-A0003); Black: linker)

HY-157764

*PROTAC ATR* degrader-1**	PROTACs ATM/ATR	Cancer
PROTAC ATR degrader-1 (compound ZS-7) is a potent PROTAC degrader of ataxia telangiectasia and Rad3-related (ATR), with DC₅₀ of 0.53 μM. PROTAC ATR degrader-1 plays an importnt role in cancer research .

HY-157767

Abd110	PROTACs ATM/ATR	Cancer
Abd110 (compound 42i) is a Lenalidomide-based *PROTAC ATR* kinase** degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .

HY-172448

YY2201	ATM/ATR	Cancer
YY2201 is a highly potent and selective *ATR* inhibitor with an IC₅₀ of 8 nM. YY2201 shows >200-fold more selective for ATR than mTOR. YY2201 inhibits tumor progression in broad-spectrum cancer types (such as lung cancer) .

HY-101566S

Elimusertib-d3 BAY 1895344-d₃	ATM/ATR	Cancer
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-167635

Decarbamoylmitomycin C	MDM-2/p53 Drug Derivative ATM/ATR	Cancer
Decarbamoylmitomycin C, an analog of Mitomycin C (MC), is an DNA-alkylating agent. Decarbamoylmitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction .

HY-13816

NU6027	CDK ATM/ATR	Cancer
NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K_is of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of *ATR* and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .

HY-W011425

NTPO Nitrilotris(methylenephosphonic acid)	DNA Alkylator/Crosslinker	Cancer
NTPO (Nitrilotris methylenephosphonic acid) is a DNA damage inducer, causing genomic DNA damage and fragmentation, activating ATR-mediated cell cycle checkpoints. The DNA damaging effects of NTPO are abrogated by base excision repair (BER) but not nucleotide excision repair (NER) .

HY-161138

WK369	BCL6 Apoptosis	Cancer
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .

HY-RS22238

Mmab Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mmab Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mmab gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mmab Mouse Pre-designed siRNA Set A Mmab Mouse Pre-designed siRNA Set A

HY-15520

CGK733 5+ Cited Publications	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

HY-19323

Ceralasertib Maximum Cited Publications 50 Publications Verification AZD6738	ATM/ATR	Cancer
Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of *ATR* kinase with an IC₅₀ of 1 nM.

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

2,391 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,391 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L004

Cell Cycle/DNA Damage Compound Library

2,713 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 2,713 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name	Type

HY-W011425A

NTPO trisodium Nitrilotris(methylenephosphonic acid), trisodium salt	Chelators
NTPO trisodium is a DNA damage inducer, causing genomic DNA damage and fragmentation, activating ATR-mediated cell cycle checkpoints. The DNA damaging effects of NTPO trisodium are abrogated by base excision repair (BER) but not nucleotide excision repair (NER) .

HY-W011425B

NTPO, 25mM Solution, PCR Grade

Nitrilotris(methylenephosphonic acid), 25mM Solution, PCR Grade

Gene Sequencing and Synthesis

NTPO, 25 mM Solution, PCR Grade (Nitrilotris(methylenephosphonic acid), 25 mM Solution, PCR Grade) A 25 mM solution prepared from NTPO (HY-W011425) free of DNase, RNase and phosphatase contamination, suitable for molecular biology research. NTPO is a DNA damage inducer that causes genomic DNA damage and breaks, activating ATR-mediated cell cycle checkpoints. The DNA damage effect of NTPO can be eliminated by base excision repair (BER) but not nucleotide excision repair (NER) .

Cat. No.	Product Name	Target	Research Area

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of *ATR* (Ataxia Telangiectasia and Rad3 related) protein kinase (K_i=6 nM). ATR kinase substrate peptide inhibits *ATR* activity by competing with *ATR* kinase ATP-binding sites to block *ATR* mediated signaling. ATR kinase substrate peptide can be used to study the role of *ATR* kinase in DNA damage response .

Cat. No.	Product Name	Target	Research Area

HY-P991272

ATR-107	Interleukin Related	Inflammation/Immunology
ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). ATR-107 is promising for research of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N7046

Silybin B Silibinin B	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Amyloid-β Apoptosis JNK p38 MAPK
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-118921

Ovatodiolide	Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants Artemisia persica Boiss.	Apoptosis
Ovatodiolide is a compound that can be isolated from Anisomeles indica. Ovatodiolide has anti-bacterial and anti-inflammatory properties. Ovatodiolide also has anti-cancer activity that induces cell cycle G2/M arrest and apoptosis via a ROS-dependent ATM/ATR signaling pathways .

HY-B0255

Adefovir dipivoxil 1 Publications Verification GS 0840	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	HBV Orthopoxvirus HSV DNA/RNA Synthesis ATM/ATR CDK
Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-N6954

Garcinone C 2 Publications Verification	Structural Classification other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Guttiferae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	ATM/ATR STAT CDK Hedgehog
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

HY-N7046R

Silybin B (Standard) Silibinin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae	Reference Standards JNK Amyloid-β p38 MAPK Apoptosis
Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and *ATR* pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-B0255R

Adefovir dipivoxil (Standard) GS 0840 (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards HBV Reverse Transcriptase Orthopoxvirus Endogenous Metabolite
Adefovir dipivoxil (Standard) is the analytical standard of Adefovir dipivoxil. This product is intended for research and analytical applications. Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the *ATR* signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer .

HY-N6954R

Garcinone C (Standard)	Structural Classification other families Xanthones Garcinia oblongifolia Champ. ex Benth. Guttiferae Source classification Phenols Polyphenols Plants	Reference Standards ATM/ATR STAT CDK Hedgehog
Garcinone C (Standard) is the analytical standard of Garcinone C. This product is intended for research and analytical applications. Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of *ATR* and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active .

Species:	Human (3)
Tag:	His (2) Avi (1) Fc (1)
Source:	HEK293 (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P7521A

	TEM8/ANTXR1 Protein, Human (HEK293, His) rHuAnthrax toxin receptor 1, His; ANTXR1; ATR; Anthrax toxin receptor 1	Human	HEK293
	The TEM8/ANTXR1 protein is multifunctional in cell attachment and migration, interacting with extracellular matrix proteins and the actin cytoskeleton. This binding mediates cell adhesion to type 1 collagen and gelatin, promoting actin cytoskeletal reorganization and cell spreading, which is critical for cell structure and movement. TEM8/ANTXR1 Protein, Human (HEK293, His) is the recombinant human-derived TEM8/ANTXR1 protein, expressed by HEK293, with C-6*His labeled tag.

HY-P77226

	TEM8/ANTXR1 Protein, Human (HEK293, Fc) ANTXR1; ATR; Anthrax toxin receptor 1	Human	HEK293
	The TEM8/ANTXR1 protein is multifunctional in cell attachment and migration, interacting with extracellular matrix proteins and the actin cytoskeleton. This binding mediates cell adhesion to type 1 collagen and gelatin, promoting actin cytoskeletal reorganization and cell spreading, which is critical for cell structure and movement. TEM8/ANTXR1 Protein, Human (HEK293, Fc) is the recombinant human-derived TEM8/ANTXR1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P705240

	TEM8/ANTXR1 Protein, Human (Biotinylated, HEK293, His-Avi) rHuAnthrax toxin receptor 1, His; ANTXR1; ATR; Anthrax toxin receptor 1	Human	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-101566S

Elimusertib-d3
Elimusertib-d3 (BAY 1895344-d3) is the deuterium labeled Elimusertib (BAY 1895344). Elimusertib is a potent, orally active and selective ATR inhibitor and has anti-tumor activity .

HY-N7046S

Silybin B-d3

Silybin B-d₃ (Silibinin B-d₃) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-W766548

Floxuridine-13C,15N2

Floxuridine- ¹³C, ¹⁵N₂ (5-Fluorouracil 2'-deoxyriboside- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P87024

	*Phospho-ATR* (T1989) Antibody (YA6717)** Ataxia telangiectasia and Rad3 related antibody; Ataxia telangiectasia and Rad3-related protein antibody; ATR antibody; ATR_HUMAN antibody; FCTCS antibody; FRAP Related Protein 1 antibody; FRAP-related protein 1 antibody; FRP1 antibody; MEC1 antibody; MEC1 mitosis entry checkpoint 1 homolog antibody; Ataxia telangiectasia and Rad3 related antibody; Ataxia telangiectasia and Rad3-related protein antibody; ATR antibody; ATR_HUMAN antibody; FCTCS antibody; FRAP Related Protein 1 antibody; FRAP-related protein 1 antibody; FRP1 antibody; MEC1 antibody; MEC1 mitosis entry checkpoint 1 homolog antibody; Protein kinase ATR antibody; RAC3 antibody; Rad3 related protein antibody; SCKL antibody; SCKL1 antibody; Serine/threonine protein kinase ATR antibody; Serine/threonine-protein kinase ATR antibody	WB, ICC/IF	Human